June 1 (Reuters) - Replimune Group Inc REPL.O:
REPLIMUNE PRESENTS NEW ANALYSES FROM THE IGNYTE STUDY OF RP1 PLUS NIVOLUMAB IN ANTI-PD1 FAILED MELANOMA AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
REPLIMUNE GROUP INC - RP1 PLUS NIVOLUMAB SHOWS ROBUST RESPONSES IN INJECTED AND NON-INJECTED LESIONS
REPLIMUNE GROUP INC - RP1 PLUS NIVOLUMAB SHOWS 32.9% ORR IN ANTI-PD-1 FAILED MELANOMA PATIENTS
Source text: ID:nGNXbBx1PL
Further company coverage: REPL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.